Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Interest & Investment Income (2024 - 2025)

BioNexus Gene Lab's Interest & Investment Income history spans 2 years, with the latest figure at $20778.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 40.67% year-over-year to $20778.0; the TTM value through Sep 2025 reached $108011.0, changed N/A, while the annual FY2024 figure was $147641.0, 114.99% up from the prior year.
  • Interest & Investment Income for Q3 2025 was $20778.0 at BioNexus Gene Lab, down from $29768.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $49739.0 in Q2 2024 and bottomed at $20778.0 in Q3 2025.